Quince Therapeutics, Inc.
QNCX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8 | $7 | $8 | $6 |
| G&A Expenses | $0 | $3 | $5 | $0 |
| SG&A Expenses | $3 | $3 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $2 | $0 |
| Operating Expenses | $11 | $10 | $15 | $10 |
| Operating Income | -$11 | -$10 | -$15 | -$10 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2 | -$6 | -$0 | -$2 |
| Pre-Tax Income | -$13 | -$16 | -$15 | -$12 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$13 | -$16 | -$15 | -$12 |
| % Margin | – | – | – | – |
| EPS | -0.25 | -0.34 | -0.34 | -0.28 |
| % Growth | 26.5% | 0% | -21.4% | – |
| EPS Diluted | -0.25 | -0.34 | -0.34 | -0.28 |
| Weighted Avg Shares Out | 54 | 47 | 44 | 43 |
| Weighted Avg Shares Out Dil | 54 | 47 | 44 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$13 | -$16 | -$13 | -$12 |
| % Margin | – | – | – | – |